Can peripheral leukocytes be used as Alzheimer's disease biomarkers?
Alzheimer's disease (AD) is the leading cause of dementia in elderly populations throughout the world and its incidence is on the rise. Current clinical diagnosis of AD requires intensive examination that includes neuropsychological testing and costly brain imaging techniques, and a definitive diagnosis can only be made upon postmortem neuropathological examination. Additionally, antemortem clinical AD diagnosis is typically administered following onset of cognitive and behavioral symptoms. As these symptoms emerge relatively late in disease progression, therapeutic intervention occurs after significant neurodegeneration, thereby limiting efficacy. The identification of noninvasive diagnostic biomarkers of AD is becoming increasingly important to make diagnosis more widely available to clinics with limited access to neuropsychological testing or state-of-the-art brain imaging, reduce the cost of clinical diagnosis, provide a biological measure to track the course of therapeutic intervention, and most importantly, allow for earlier diagnosis--possibly even during the prodromal phase--with hopes of therapeutic intervention prior to appreciable neurodegeneration. Circulating leukocytes are attractive candidate AD biomarkers as they can be obtained in a minimally invasive manner and are easily analyzed by widely available flow cytometry techniques. In this review, we critically analyze the potential utility of peripheral leukocytes as biological markers for AD.
Rezai-Zadeh
Kavon
K
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. rezaik@cshs.org
Gate
David
D
Szekely
Christine A
CA
Town
Terrence
T
D000544:Alzheimer Disease / Q000097:blood* / Q000276:immunology*; D000818:Animals; D015415:Biomarkers / Q000097:blood; D006801:Humans; D007962:Leukocytes / Q000276:immunology*; D010641:Phenotype
D015415:Biomarkers